SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Omkar Pharmachem Ltd (532167)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 532167 NSE: Business Support | Small Cap | Omkar Pharmachem Share Price

₹23.55 -0.82 (-3.36%)

As on 04-Jun'26 16:59

Omkar Pharmachem Ltd (532167)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 532167 NSE: Business Support | Small Cap | Omkar Pharmachem Share Price

₹23.55 -0.82 (-3.36%)

As on 04-Jun'26 16:59

Key Metrics
Valuation Multiples
Market Cap
₹24 Cr.
Current Price
₹23.6
52-Week Low / High
₹23 / 30
TTM EPS
₹0.1
TTM Sales
₹0 Cr.
Book Value per Share
₹36.3
P/E Ratio
196.28
Higher than its 5-year historical median
Industry PE
23
Price to Book (P/B)
0.65
Lower than its 5-year historical median
Price to Sales (P/S)
0.00
EV/EBITDA
140.91
Higher than its 5-year historical median
Dividend Yield
0.00%
Profitability Efficiency
Return on Equity (ROE)
2.15%
Underperforms industry median
Return on Capital Employed (ROCE)
3.02%
Underperforms industry median
Return on Assets (ROA)
2.11%
Operating Profit Margin
53.9%
Net Profit Margin
37.2%
Gross Profit Margin
50.9%
Growth Momentum
1-yr vs 3-yr growth
Sales Growth (1 Year)
Steady versus 3-year growth rate
0%
Operating Profit Growth (1 Year)
Improving versus 3-year growth rate
3.57%
Net Profit Growth (1 Year)
Improving versus 3-year growth rate
5.26%
Asset Quality
Promoter Holding
0.03%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹27 Cr.
Equity
₹10.1 Cr.
Face Value
₹10
All Time Low / High
₹1.50 / 30.09

Omkar Pharmachem stock performance

Key Ratios
mw4me loader

Check Before You Invest

M-Cap below 100cr DeciZen not available

Q.1 Is Omkar Pharmachem Ltd a good quality company?
Omkar Pharmachem Ltd is a quality company, based on a multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

  • How has it performed on generating Profits?

    By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.

  • How efficiently has it utilized Capital?

    By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.

  • How is it managing its Debt?

    By checking its Debt to Equity and Cash Flow from Operations.

How does Omkar Pharmachem Ltd performance compare with that of its Peers?
Q.1 Revenue growth of Omkar Pharmachem Ltd vs industry peers?
Omkar Pharmachem Ltd revenue CAGR is 60.95%, compared to the industry median CAGR of 0.35%, indicating faster growth and gaining its market share.
Q.1 Promoter shareholding and pledge status of Omkar Pharmachem Ltd?
Promoters hold 0.03% of the Omkar Pharmachem Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Q.1 Stock return of Omkar Pharmachem Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 16.1% based on the current price.

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Omkar Pharmachem Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % -1.3%2.9%-2.6%-4.1%-2.2%0.2%2.8%3.2%2.9%3%-
Value Creation
Index
-1.1-0.8-1.2-1.3-1.2-1.0-0.8-0.8-0.8-0.8-

Growth Parameters

Sales 00000.10.30.50.50.50.50
Sales YoY Gr.-NANANANA440%100%0%0%0%-
Adj EPS -0.1-0.1-0.3-0.4-0.30.20.20.20.20.20.1
YoY Gr.-NANANANANA-18.2%11.1%-5%5.3%-
BVPS (₹) 9.19.39.18.68.48.68.899.29.436.3
Adj Net
Profit
-0.1-0.1-0.3-0.4-0.30.20.20.20.20.20
Cash Flow from Ops. 0.3-0.8-0.3-0.3-0.200.20.30.30.2-
Debt/CF from Ops. 00-1-1.9-4.140.34.62.310.5-

CAGR

9 Years 5 Years 3 Years 1 Years
Sales NA61%0%0%
Adj EPS NANA3.6%5.3%
BVPS0.3%2.3%2.2%2.2%
Share Price 14.5% 3.4% -2% -15.5%

Key Financial Parameters

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
-1.3-1.3-2.8-4.7-32.62.12.22.12.20.5
Op. Profit
Mgn %
0000-454.28.149.857.652.653.9NAN
Net Profit
Mgn %
0000-576.98233.936.63537.2INF
Debt to
Equity
0000.10.10.10.10.1000
Working Cap
Days
00007330377182910
Cash Conv.
Cycle
000010-43-18-12-3190

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Sales00000.050.270.540.540.540.54
Operating Expenses + 0.120.220.240.380.250.250.270.230.260.25
Manufacturing Costs0000000000
Material Costs0000000000
Employee Cost 0.030.140.140.190.150.150.170.140.160.16
Other Costs 0.090.080.100.190.100.100.100.090.100.09
Operating Profit -0.12-0.22-0.24-0.38-0.200.020.270.310.280.29
Operating Profit Margin (%) -----454.0%8.1%49.8%57.6%52.6%53.9%
Other Income + 00.0100000000
Exceptional Items 00.4800000000
Interest 000.010.040.050.060.060.050.030.02
Depreciation 0000000000.01
Profit Before Tax -0.120.27-0.25-0.42-0.26-0.040.210.260.250.27
Tax 00.050-00-0.260.030.070.060.07
Profit After Tax -0.120.22-0.26-0.42-0.260.220.180.200.190.20
PAT Margin (%) -----576.0%82.0%33.9%36.6%35.0%37.2%
Adjusted EPS (₹)-0.10.2-0.3-0.4-0.30.20.20.20.20.2
Dividend Payout Ratio (%)0%0%0%0%0%0%0%0%0%0%

Valuation of Omkar Pharmachem - Standalone

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Analyst's Notes

data not found
No data found!

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund + 9.169.389.128.708.448.668.859.049.239.43
Share Capital 10.0810.0810.0810.0810.0810.0810.0810.0810.0810.08
Reserves -0.93-0.71-0.96-1.38-1.64-1.42-1.24-1.04-0.85-0.65
Debt +000.240.580.870.900.930.620.300.12
Long Term Debt0000000000
Short Term Debt000.240.580.870.900.930.620.300.12
Minority Interest0000000000
Trade Payables0.040.030.020.020.030.030.020.040.020.01
Others Liabilities 0.520.020.020.020.02-0.22-0.20-0.14-0.060.01
Total Liabilities 9.729.439.409.329.369.379.609.579.499.57

Fixed Assets

Net Fixed Assets +0.0100.010000.0100.010.01
Gross Block0.010.010.010.010.010.010.020.020.030.03
Accumulated Depreciation0000.010.010.010.010.020.020.03
CWIP 0000000000
Investments 9.309.309.309.309.309.309.309.309.309.30
Inventories0000000000
Trade Receivables0.070.070.0700.020.030.080.130.050.10
Cash Equivalents 0.330.050.020.020.040.040.210.130.070.11
Others Assets 0000-00000.060.06
Total Assets 9.729.439.409.329.369.379.609.579.499.57

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity + 0.34-0.77-0.25-0.30-0.210.020.200.280.300.24
PBT -0.12-0.21-0.25-0.42-0.26-0.040.210.260.250.27
Adjustment 0-00.020.120.050.060.060.050.030.02
Changes in Working Capital 0.46-0.51-0.010.01-0.010-0.07-0.040.01-0.05
Tax Paid 0-0.05-00000000
Cash Flow From Investing Activity + 00.49-0.010-00-0.010-0.01-0
Capex 00.49-0.010-00-0.010-0.01-0
Net Investments 0000000000
Others 0000000000
Cash Flow From Financing Activity + -0.010.010.230.300.24-0.02-0.03-0.35-0.35-0.20
Net Proceeds from Shares 0000000000
Net Proceeds from Borrowing 0000000000
Interest Paid 00.01-0.01-0.04-0.05-0.06-0.06-0.05-0.03-0.02
Dividend Paid 0000000000
Others -0.0100.240.340.290.040.03-0.31-0.32-0.18
Net Cash Flow 0.33-0.28-0.0300.0200.17-0.08-0.060.04

Financial Ratio

PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)-1.272.38-2.77-4.72-3.032.592.092.212.072.15
ROCE (%)-1.272.91-2.55-4.11-2.220.222.763.22.943.02
Asset Turnover Ratio000000.030.060.060.060.06
PAT to CFO Conversion(x)N/A-3.5N/AN/AN/A0.091.111.41.581.2
Working Capital Days
Receivable Days000014630.4036.5071.2060.2049.30
Inventory Days0000000000
Payable Days0000000000

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Omkar Pharmachem Ltd FAQs

The current trading price of Omkar Pharmachem on 04-Jun-2026 16:59 is ₹23.55.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 03-Jun-2026 the market cap of Omkar Pharmachem stood at ₹23.75 Cr

The latest P/E ratio of Omkar Pharmachem as of 03-Jun-2026 is 196.3.

The latest P/B ratio of Omkar Pharmachem as of 03-Jun-2026 is 0.65.

The 52-week high of Omkar Pharmachem is ₹29.74 and the 52-week low is ₹23.16.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Omkar Pharmachem is ₹0.00 ( Cr.) .

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Omkar Pharmachem Ltd is a below average quality company.

The key valuation ratios of Omkar Pharmachem Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Omkar Pharmachem Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

About Omkar Pharmachem Ltd

Omkar Pharmachem was incorporated in 1994, it is located in New Delhi. The manufacturing unit developed the capacity to manufacture sodium bi-sulphite, sodium meta bi-sulphite, sodium sulphite, and sulphur.

In the financial year 2007, the company did not conduct any manufacturing or other business activity due to tough market conditions. It has further decided to discontinue commercial activity and wait till an appropriate business environment is established.

The registered office of the company is located at Mahakant Building, 501, Ashram Road opposite V S Hospital Ellisbridge Ahmedabad, Gujarat 380006.

Business area of the company

The company is engaged in the manufacturing of pharmaceutical chemicals.

To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×